ashish kolte

Oral Solid Dosage Contract Manufacturing Market Is Appraised To Be Valued US$ 7,201.1 Mn By 2028

2020-06-17T10:05:05.325Z

New York City, United States -- With the outbreak of COVID-19 in worldwide and stipulated lockdown, the healthcare sector is witnessing an unprecedented slowdown as per EY-FICCI study titled, ‘COVID-19 impact assessment for healthcare sector and key financial measures recommendations for the sector’. The study is predicated on an assessment of healthcare players within the country to assess the economic impact of the COVID-19 pandemic and provides recommendations on the fiscal stimulus measures it needs within the coming months.

Market consolidation strategies to be centered around acquisition of key technologies and specialty pharma companies.

Solid dosage continues to remain the most preferred drug delivery form, used across a wide spectrum of pharmaceutical landscape, pushing the global oral solid dosage (OSD) contract manufacturing market to a promising US$ 21.5 Billion cap, in 2019, predicts Persistence Market Research, in its recently released study on the global oral solid dosage contract manufacturing landscape.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25768

Company Profiles

Recipharm AB
AbbVie Contract Manufacturing
Patheon N.V.
Catalent Inc.
NextPharma
Capsugel (Lonza Group AG)
Aurobindo Pharma Limited (AuroSource)
Siegfried AG
Piramal Pharma Solutions
CordenPharma
Others.

Apart from being more cost-effective (compared to the novel treatment alternatives and increasing number of biologics) and patient complaint, oral dosage provides increased physical and chemical stability, controlled-release options, and superior ease of handling.

The global oral solid dosage contract manufacturing market is estimated to grow at a high CAGR of 5.8 percent, through the forecast period of 2017-2028.

“The market will continue to perform immensely well, given the unrivaled demand for generics, in the coming years. Key companies operating in the oral solid dosage contract manufacturing landscape, anticipate substantial market growth through 2028, given the growing demand in emerging markets, continuing novel pharmaceutical formulations, and industry consolidation”, Principal Analyst, Pharmaceutical Domain, Persistence Market Research

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25768

The global market for oral solid dosage contract manufacturing presents a highly fragmented landscape, wherein approximately 11 percent tier-1 leaders including Patheon N.V., AbbVie Inc., Catalent Inc., Piramal Enterprises, Capsugel (Lonza), and AuroSource hold a lion’s share of nearly 63 percent. In addition, tier-2 and tier-3 players contribute approximately 12 percent and 25 percent to the total market share, respectively. Their key forward market strategies include,

Increased research and development activities by US-based pharmaceutical companies translating into a number of mergers—aimed at scaling production capacity of New Chemical Entities (NCEs).
Innovator companies outsourcing active pharmaceutical ingredient (API) and formulation manufacturing is resulting in nearly 60 percent cost cutting.
Long-term contract manufacturing partnerships between companies, is expected to remain a critical demand growth strategy—with most CMOs building contract manufacturing facilities for pharmaceutical companies. The trend is mostly prevalent in the North American oral solid dosage contract manufacturing landscape
Product differentiation, in a fragmented landscape, would help companies to solidify their market position in oral solid dosage contract manufacturing market, globally.
Consolidation remains a perennial issue for the CMO and contract development and manufacturing organization (CDMO), wherein acquisitions of either a standing provider or an existing pharmaceutical facility will dominate the oral solid dosage contract manufacturing landscape, specifically in US.
Big pharma are projected to balance their product portfolios and make substantial investments in their core capabilities.
CMOs are likely to strive hard to keep up with regulatory compliances—posing both as a challenge and opportunity for them.
Partnerships with third-party distributors will remain a highly adopted model.

“In the global oral solid dosage contract manufacturing landscape, approximately 64 percent contract manufacturing organizations (CMOs) pursue contract manufacturing as their primary business.

The remaining 36 percent offer contract manufacturing in production facilities where they manufacture their own products. Of 280 largest CDMOs only 12.5 percent operate on global level i.e. their manufacturing and business development activities cover multiple geographical regions. Majority of medium to small size CMOs focus to serve their immediate markets”, the principal analyst explained further.

Novel technologies in the form of sublingual tablets and extended release beads in capsules are anticipated to benefit OSD contract manufacturers to either introduce new products or revive their older products.

Apart from catering well to the patient segment having difficulties in swallowing tablets, including pediatric patients, extended release beads help in optimizing release rate, while reducing initial dose spike. Sublingual tablets delivers quick medication, mostly used in pain management applications. Innovators are also betting on Amorphous solid dispersions (ASDs), providing them with more efficient solubility and stability, translating into safer drugs with enhanced efficacy.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25768

Insights from Segmentation Analysis of Oral Solid Dosage (OSD) Contract Manufacturing Market

Tablet remain the most commonly preferred dosage form given the growing demand for specialized dosage forms including pediatric tablets and orally disintegrating tablets. By dosage form, tablets are expected to generate a revenue of US$ 11.2 Bn, in 2019, with immediate tablets contributing the maximum revenue share.
By end-user, small & medium size pharma and biotech companies will remain the most lucrative customers, in terms of revenue generation for oral solid dosage (OSD) contract manufacturing, considering small & medium pharma companies lack full-potential manufacturing facilities.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Elder Care Services Market – Elder Care Services Market Segmented By Home-based Care, Community-based Care, Institutional Care Services and Financing Source By Public Expenditure, Private Source, Out-of-Pocket Spending. For More Information About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Facial Bone Contouring Market Revenue Is Expected To Reach US$ 50 Mn By 2026

2020-06-17T10:05:02.460Z

Catering to a niche population, the global demand for facial bone contouring is expected to remain rather sluggish, through 2019—risks and complications associated with surgeries, premium pricing, and lack of trained professionals being the top three market restrainers.

Likely revenue generated through facial bone contouring procedures, carried out globally, is projected to reach a revenue of US$ 409.4 Mn, in 2019, representing an annual growth of 1.9 percent, as indicated by a recently released market study by Persistence Market Research (PMR), covering the facial bone contouring landscape. PMR offers a comprehensive analysis of the global facial bone contouring market, for a timeline of eight years, 2018-2026.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25765

Classified into:

Zygomatic Bone Surgery
Mentoplasty and Genioplasty
Rhinoplasty
Maxilla and Mandible Surgery

“Most of the appearance enhancement surgeries are known to be carried out in USA, Brazil, Japan, Mexico and Italy, followed by Thailand, Germany, and Colombia. On the other hand, surgeons associated with America Society of Plastic Surgeons—suggest substantial increase in the number of facial done contouring procedures, specially undertaken by those under the age of 30 years. Skewed international beauty standards are increasingly placing younger groups of patients under pressure to look a certain way. However, the growing ‘celebrity culture’ is the most important underlying reason, driving the demand for facial bone contouring procedures”, explained a senior analyst of the company.

Regionally, Latin America is expected to remain the most lucrative market for facial bone contouring, followed by APAC. On the other hand, women in MEA opting for rhinoplasty surgeries is expected to be majorly responsible for the facial bone contouring market expansion, in the region.

The MEA facial bone contouring market is expected to grow at a CAGR of 3.3 percent, highest among all regions, over the forecast period, standing at a valuation of nearly US$ 50 Mn, by 2026.

PMR Identifies Critical Market Restrainers

Risks and post-operative complications in the form of asymmetry, swelling, bruising, and hematoma associated with facial bone contouring procedures.
Absence of favorable reimbursement policies for aesthetic surgeries in underdeveloped and developing countries could hamper the adoption of facial bone contouring, as premium pricing of such surgeries remain a key concern.
Lack of certified medical professionals, also resulting in malpractices will significantly impact the facial bone contouring landscape, as per the report.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25765

Key Surgeries Addressed Using Facial Bone Contouring

Classified into:

Zygomatic Bone Surgery
Mentoplasty and Genioplasty
Rhinoplasty
Maxilla and Mandible Surgery

The report by PMR indicates that zygomatic bone surgeries are expected to dominate the facial bone contouring landscape, in 2019, in terms of revenue—with most of such procedures conducted in Asian countries.

The revenue generated through zygomatic bone surgeries is expected to reach a valuation of US$ 125.7 Mn, during the same period. However, maxilla and mandible surgery is poised to represent a relatively higher adoption, compared to zygomatic bone surgeries, thereby growing at a CAGR of 2.8 percent, through 2026.

The trend is likely to be followed by rhinoplasty—representing an attractiveness index of 1.23, through the forecast period. The maxilla & mandibular surgery segment is the fastest growing segment among the surgery type in APAC considering growing demand of this particular form of facial bone contouring procedure among Asian population.

The Asia Pacific region is witnessing increasing popularity of V-shaped chin and ‘westernized facial features’, thereby, increasing the demand for facial bone contouring procedures in the region.

“However, apart from facial bone contouring surgeries performed for beautification reasons, they are also carried out to correct facial bones and repair their functionalities. Application of facial bone contouring to correct any genetic facial fractures or disorders, is also a key driving factor.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25765

Correction of nasal structure for normal breathing and treating cleft palate defects are some common abnormalities considered under the application scope of facial bone contouring”, the analyst explained further.

Opportunity Analysis: Persistence Market Research foresees immense growth potential for facial bone contouring in the coming years, considering increase in production of clinically proven products and growing number of patients rejecting ‘one size for all’ approach and opting for facial-bone specific enhancements with procedures with successful clinical record.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Dental Lasers Market To Extend An Assessed Value Of US$ 409 Mn By 2026

2020-06-17T10:04:59.279Z

The global demand for dental lasers is anticipated to grow moderately, in 2019, representing a growth rate of approximately 4.5 percent. As per a recently released in-depth analysis of the global dental lasers adoption by Persistence Market Research, the dental lasers market is expected to exceed the valuation of US$ 409 Mn—the market growth rate standing at 1.4X, through the assessment period of 2018-2026.

“The growing demand rate can safely be attributed to exploding laser application to treat dental diseases, including restorative removal and curing, caries prevention, dentinal hypersensitivity, cavity preparation, growth modulation, and other diagnostic purposes—all constituting hard tissue applications.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25699

Company Profiles

Biolase, Inc
Dentsply Sirona
AMD LASERS
A.R.C. Laser
Convergent Dental
IPG Photonics Corporation
Elexxion AG
Laserstar Technology
J. MORITA CORP.
Fotona d.o.o.
Den-Mat Holdings LLC
Others.

Dental lasers have also found increased adoption in soft tissue application comprising wound healing, photodynamic therapy for malignancies, removal of hyperplastic tissue, and photostimulation of herpetic lesion.

Apart from demonstrated procedure specificity, dental lasers have proved to be an effective tool owing to increased efficiency, comfortable dental treatment, more soft tissue control, and less bleeding”, explained a senior analyst of the company.

PMR foresees further growing dental lasers landscape—presently, at a high state of refinement considering substantial state of refinement. Moreover, laser-based photochemical reactions is expected to bring promising new results in dentistry applications, aimed at targeting cells, molecules, and pathogens. Moreover, conservative soft tissue procedures using dental laser being covered under several insurance policies, is likely to drive dental lasers demand growth, the analyst further explains.

While diode lasers continue to remain a hit in dentistry, PMR also anticipates increasing prominence showcased by Nd:YAG Lasers, followed by Er:YAG—all falling under dental surgical lasers segment. Analysis of the global dental lasers market, projects dominance by dental surgical lasers, holding a whopping 80 percent of the total market share.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25699

Soft tissue procedures carried out using diode lasers, through 2026, is projected to generate a revenue of approximately US$ 196 Mn, globally, considering its effectiveness in treating periodontal diseases. Moreover, labial frenectomy conducted using diode laser is known to significantly reduce suturing during intervention and bleeding. Further, resulting in substantially lesser intervention time, less post-operative pain and discomfort—translating into faster operative wound healing.

“Varying wavelength of diode lasers result in different levels of water absorption and efficacy of diode lasers is highly dependent on clinically managing and evaluating the biocompatibility and sterility of the char along with biocompatibility of the glass”, further explains the analyst. Er:YAG Lasers, a substitute for acid etching of enamel, and CO2 Lasers have showed significant success rate in dental procedures, versus Nd:YAG Lasers, which is contraindicated as it causes temperature build-up around the implants, resulting in melting of implant surface, in spite of its excellent sterilization characteristics.

Since, comfortable and minimally invasive procedures are the are an important goal of dental lasers, Er:YAG lasers have the ability to provide conservative restorative treatments, in hard tissue application, placing it in a fast moving growth pedestal, according to the study.

A highly consolidated dental laser landscape, is controlled by top three key players, including Biolase, Inc, Dentsply Sirona, and AMD Lasers—holding an approximate market share of 87 percent. Biolase, Inc, is the unrivaled player in the dental lasers market, with nearly 53 percent market share.

On the other hand, Dentsply Sirona and AMD Lasers, collectively hold dominance over 34 percent market share. High market consolidation is characterized by high technological intensity and proprietary technology, as per the report.

The companies are focusing on technologically advanced new products to strengthen the product portfolio and solidify their market position, with a key focus on the emerging markets of Asia Pacific. Moreover, regional expansions, strategic collaboration, and mergers and acquisitions will also remain core forward market strategies.

Dentsply Sirona announced the acquisition of Healthdent Technologies International, perfectly complementing Dentsply Sirona’s endodontics and restorative portfolio. The company, in 2018, expanded in North America, Shanghai, Italy, Austria, and Germany, further broadening its regional reach.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25699

Market Restrainers

Apart from such technological innovations, PMR anticipates that easy availability of alternative products such as, anesthetics, dental probes, dental drills, and scalpels coupled lack of technical expertise in handling dental lasers could significantly impede the dental lasers market growth.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Rosacea Treatment Market Is Expected To Surpass US$ 733.9 Mn By 2026

2020-06-17T10:04:56.329Z

The FDA recently approved Oxymetazoline, employed in the rosacea-related persistent facial erythema in adults.
Soolantra (topical ivermectin) received the FDA approval recently, for the use in the treatment of inflammatory lesions of rosacea.
The FDA’s approval for a topical cream RHOFADE (Oxymetazoline Hydrochloride) paved the way for the drug in the rosacea therapeutics, exclusively for persistent facial erythema in adults.
A tentative approval by the FDA has allowed the inclusion of Zenavod capsules (doxycycline) in rosacea therapeutics. These capsules are particularly used against pustules and papules, i.e. the specific inflammatory lesions associated with the condition in adults.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/18793

Company Profiles

Foamix Pharmaceuticals Ltd.
SONOMA PHARMACEUTICALS, INC.
Allergan plc
Pfizer Inc.
Nestlé Skin Health (Galderma S.A.)
Bayer AG
Mylan N.V.
Janssen Pharmaceuticals, Inc.
Teva Pharmaceuticals Company
Others.

While these FDA approvals for rosacea therapeutics were registered in 2017, the decently growing rate of the introduction of new FDA-approved drugs is likely to provide a strong push to the revenue expansion of rosacea therapeutics landscape.

With an expanding rosacea patient pool, most prominently in Europe and North America, the revenue growth prospects for global rosacea therapeutics landscape appear to be on an impressive trajectory over the coming years. In a new intelligence report published by Persistence Market Research (PMR), the global sales of rosacea therapeutics are likely to receive major benefits from the development of newer formulations of rosacea therapeutics, especially alpha agonists.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/18793

A senior research analyst at PMR says, “The largest business opportunity is created by the increasing rosacea instances subsequently followed by inadequate definite curative therapeutics, insufficiently satisfactory as a first-line treatment. Rosacea therapeutics market players are targeting this opportunity leading to strategic new drug developments”.

In the consolidated competitive landscape of rosacea therapeutics market, four leading companies account for over 75% share of the total market value, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Foamix Pharmaceuticals Ltd., and Bayer A.

PMR’s report on global rosacea therapeutics market provides deep-dive insights on the competitive landscape through thorough key company profiling and evaluation of their recent strategic developments.

“The available range of drugs in rosacea therapeutics necessarily play a palliative, short-term role in addressing the consequences of rosacea. However, the current treatment line still fails to provide a long-term therapy, let alone target the root cause of rosacea. The rosacea therapeutics space has been constantly witnessing R&D efforts with an objective to break through this ever-unmet need, which continues to be hampered by the lack of understanding of the disease itself,” explains the analyst, further adding, “There remains a huge gap between the existing rosacea therapeutics and market demand. The rate of treatment is also significantly low, prompting at the upcoming business opportunities for rosacea therapeutics market stakeholders”.

Off-label Pharmaceuticals Favor Sales Growth of Rosacea Therapeutics Landscape

Growing use of off-label drugs is providing a strong impetus to the revenue growth of rosacea therapeutics landscape, as some of them are highly popular for use in refractory cases, including botox, corticosteroids, and sulfacetamides. While the use of off-label drugs prevails for effectively treating rosacea, it is highly non-recommended and invalid according to the FDA and a few European Medicine Agencies. Persistent use off-label, non-recommended drugs continues to elevate the demand prospects for rosacea therapeutics.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/18793

Key Insights Drawn from Global Rosacea Therapeutics Market Report

At an estimated year on year revenue growth of just-under 6%, the global demand for rosacea therapeutics is projected to account for the revenue of over US$ 2 billion in 2019.
Around 75% share of the total market revenue is held by alpha agonists and antimicrobials that are the most sought after drug classes employed in rosacea therapeutics worldwide.
Retinoids and tropicals are projected for a promising rate of adoption in coming years.
Retail sales, owing to wider penetration as a sales channel, make up for around 3/4th of the global market value.
Although the report points to a higher year over year revenue growth for institutional sales of rosacea therapeutics, the escalating pace of healthcare privatization and expanding pharmaceutical retail sales remain the key driving forces for retail growth.
Mature markets in Europe and North America hold a collective share of more than 95% in the total market revenue. However, Europe remains the top ranking region, as indicated by the report.
Key manufacturers are currently targeting these two regions for strengthening their distribution networks and thereby achieving higher RoI.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Generic Oncology Drugs Market Is Projected To Grow US$ 23 Billion By 2028

2020-06-17T10:04:52.594Z

Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology drugs will witness increased demand in the coming years

Increased spending in cancer-related research and development by various governments and private and commercial organizations combined with investments in anti-cancer drugs are the two key factors anticipated to heighten the generic oncology drugs demand, through 2019, as indicated in a recent market analysis of generic oncology drugs, by Persistence Market Research (PMR). Expanding at a robust annual rate of over 6.1 percent, the global revenue through sales of generic oncology drugs will surpass US$ 23 Billion in 2021.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25480

Company Profiles

Novartis AG
Pfizer Inc.
GlaxoSmithKline plc
CELGENE CORPORATION
Teva Pharmaceutical Industries Ltd.
Merck & Company, Inc
Aurobindo Pharma.
Hikma Pharmaceuticals PLC
Mylan N.V.
NATCO Pharma Limited.
Others.

“PMR estimates that notable product pipeline for generic oncology drugs is expected to drive lucrative business opportunities. Moreover, with industry’s pipeline reaching a historic level of late-stage development, in 2017, almost 90% of the therapies being targeted treatments and clinical success rates going up to almost 73 percent, the market for generic oncology drugs is anticipated to grow, further expanding the pipeline cancer treatment”, explained a senior research analyst.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25480

Small Molecule Generic Oncology Drugs Hold Big Opportunities in 2019

Expanding at a rather high CAGR of nearly 6.7 percent, small molecule generic oncology drugs, combing the efficacies of chemotherapy and immunotherapies could boost the ongoing cancer treatment modalities.

Although, there has been a significant development in immunotherapy alone, small molecules are expected to exceed the efficacies of large molecules and dominate the cancer treatment landscape as medical exerts continually validate the positive outcomes by combing traditional cancer treatment with new immunotherapies, thereby providing increased benefits to cancer patients.

Although PMR analysis indicates a relatively lesser market share compared to market molecules, as a modality, small molecules are likely to benefit from their cross-membrane ability, reaching greater intracellular targets.

Moreover, with a half-life of less than 24 hours, small molecules generic oncology drugs are more likely to achieve greater efficacy after a more convenient oral administration, thereby allowing researchers and clinicians to balance the side effect of combination trials through intermittent cancer treatment dosing.

“Research also indicates that more than a quarter of immune-oncology clinical trial use small as combination partners for checkpoint inhibitors, positioning itself as a unique compound class for superior immune-oncology treatments”, explains the analyst.

Potential Revenue Pockets in Emerging Economies

The generic oncology drugs landscape expanding at a robust annual growth rate of approximately 7.5 percent, APECJ along with is anticipated to present significant revenue generating avenues for drug manufacturing companies.

Increased research and development on biological and targeted drug therapies, early expiration of patents, and increasing focus on personalized treatment medication are some major factors contributing towards future avenues for generic oncology cancer drugs market in APECJ. In Japan, on the other hand, stringent regulations involving drug discovery and development process could put a spanner in generic oncology drugs market growth.

“Increasing awareness and growing demand for early cancer diagnosis is expected to translate into homegrown generic oncology drugs, thereby presenting revenue generating opportunities for local drug manufacturers. Favorable reimbursement schemes for critical drugs and significant funding for drug manufacturing infrastructure by government and private organizations of emerging economies are some key factors supplementing to the sales of generic oncology drugs. In addition, contract manufacturing initiatives for biopharmaceuticals and small molecules could broaden the future scope of generic oncology drugs”, the senior analyst further explains.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25480

Product Pipeline Expansion to Remain the Core Forward Strategy

Novartic AG, has applied channel integration strategies such as e-commerce along with the mobile app to drive sales at retail locations. Moreover, the company recently gave global rights of AKT inhibitors afuresertib and uprosertib — to the Shanghai-based company Laekna. In addition, Novartis AG received CE mark for gene-modifying therapy for blood cancer Kymriah.
Pfizer Inc., on the other hand, is focused on 39 therapies in R&D pipeline for oncology and bio similar to strengthen the core areas of the product portfolio. In 2017, Pfizer’s Glasdegib in patients with previously untreated acute myeloid leukemia received U.S FDA priority review. In the same year, company’s XTANDI (enzalutamide) too received FDA approval.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Electrophysiology Ablation Market Expected To Reach US$ 643.3 Mn By 2026

2020-06-17T10:04:48.999Z

Considered as the first line of treatment for arrhythmias, demand for electrophysiology ablation procedures is projected to increase 2X

Lying in the high growth-low revenue quadrant, the global electrophysiology ablation market is anticipated to expand at a stellar annual growth rate of 9.1 percent, standing at a valuation of US$ 2.3 Billion by 2019 end, as per a recent market analysis by Persistence Market Research.

The growing demand for electrophysiology (EP) is attributed to the advancing EP technologies with new ablation tools to improve atrial fibrillation (AF) treatments.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25474

Company Profiles

Abbott
Boston Scientific
Biosense Webster (Johnson&Johnson)
MEDTRONIC PLC
CathRx Ltd
Biotronik SE & Co. KG.
Japan Lifeline Co
ATRICURE, INC.
Auris Health
Others.

Moreover, implantable rhythm management devices for less invasive procedures combines with miniaturized diagnostic monitoring systems are also pumping revenue into the global electrophysiology ablation market. In addition, electrophysiology ablation being the first line of treatment for arrhythmias, considered superior to antiarrhythmic drugs, is anticipated to be a key factor contributing to the electrophysiology ablation procedures.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25474

Strategy Analysis through Competition Tracking

In a largely consolidated electrophysiology ablation market, key players with global recognition contribute approximately 88 percent revenue share to the global electrophysiology ablation market, with the top four players including Biosense Webster, Abbott Laboratories, MEDTRONIC PLC, and Boston Scientific Corporation contributing nearly US$ 1.1 Billion, collectively.

As per a senior research analyst, “Abbott Laboratories is expected to focus on diversification and globalization strategies by leveraging its core products. Biosense Webster Inc., on the other hand, is likely to focus on footprint expansion in emerging markets. Other leading companies including Boston Scientific Corporation and MEDTRONIC PLC are projected to focus on strategic collaborations with other key players and enhance product presence in other regions, respectively”.

Apart from the aforementioned strategies, the top four players have made advancements in heart rhythm therapy and ablation catheter, while also sustaining premium segment leadership, thereby further generating higher revenue share for electrophysiology ablation market.

Some notable developments include Abbott’s FlexAbility ablation catheters, intended for creating endocardial lesions during stimulation, mapping, and ablation procedures, Medtronic’s Arctic Front Advance Cardiac Cryoablation, and Biosense Webster’s Tag-Index Guided Ablation Software, that recently received FDA approval.

Boston Scientific Corporation observed a rise in sales, primarily driven by increased sales of next generation Rhythmia Mapping System, Rhythmia HDx, Rhythmia related disposables and their expanding portfolio of navigation enabled therapeutic catheters.

Rehospitalization after Ablation Catheter Could Pose Challenges

Considered as the most superior treatment form for patients with drug refractory scar-associated ventricular tachycardia (VT), ablation catheter is also known to result in patients developing comorbidities such as congestive heart failure (CHF) and pulmonary disease, specifically in patients with myocardial infarction-associated VT. Increased risks and complications associated with ablation catheter, translate into frequent hospital admissions and higher cumulative hospital costs.

As per PMR analysis, in terms of product type, ablation catheter segment is projected to account for nearly 48.0% revenue share of the global electrophysiology ablation market, majorly attributable to the increasing demand for them in hospitals and community set ups combined with efficient product developments, wherein newer treatments for AF use ablation catheter focusing on specific areas of the heart to yield better outcomes.

“However, several innovations and research have emerged around new mapping systems, allowing cardiologists, to view the source of atrial fibrillation. For instance, the Fixed Chaotic Sinning Approach, Atrial Fibrillation Driver Ablation, and 3-D Imaging for Ablation are some promising innovations, anticipated to determine the future of ablation catheter for AF. In the future, one could also expect robotic-driven advanced mapping and magnetic systems in the form of Stereotaxis for curing arrhythmia, amongst other novel innovations”, explained the analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25474

Opportunity Analysis: Multiple Use of Conventional Catheters

Although, the electrophysiology ablation market is dominated by the top four leading players, emerging companies are projected to develop revolutionary products, thereby broadening the application scope.

For instance, CathRx’s ground-breaking range of electrophysiology catheters called Khelix, is stated to be the first ‘reposable’ diagnostic and therapeutic catheters for the treatment of cardiac arrhythmias—allowing it to be used for 20 times in general practice of electrophysiology.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Aneurysm Clips Market Expected To Be Valued US$ XX Mn By 2028

2020-06-17T10:04:45.281Z

Rapid advancements taking place in the healthcare sector in North America are pushing revenues across medical devices markets. The region has witnessed a growth in the adoption of aneurysm clips to treat aneurysm, leading to a steady rise in revenue in the North America aneurysm clips market.

Asia Pacific Excluding Japan (APEJ) is the second most prominent region in the aneurysm clips market, with China anticipated to be the most lucrative regional market within APEJ. According to a new research released by Persistence Market Research (PMR), the market for aneurysm clips in matured economies will record comparatively lesser growth than in emerging markets.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25471

Company Profiles

Aesculap USA (B.Braun)
KLS Martin Group
AS Medizintechnik GmbH
ADCA – Indústria e Comércio de Material Cirúrgico Ltda
Ortho-Medical GmbH
Peter LAZIC GmbH
Adeor Medical AG
Rebstock Instruments GmbH
Others

PMR forecasts indicate a steady growth in revenue in the global aneurysm clips market at a sluggish rate of 1.7% during 2018–2028. Global revenue is slated to reach US$ 21.5 Mn by the end of 2018.

The report identifies key factors responsible for revenue growth of the aneurysm clips market across key geographical regions. The availability of safe and effective aneurysm clips in an assortment of sizes and shapes is fueling adoption across the healthcare sector globally. Evolution in healthcare technology is backing the manufacture of advanced aneurysm clips.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25471

Product evolution in the form of advanced raw materials used to manufacture aneurysm clips is making waves in the global aneurysm clips market. Conventional raw material used in aneurysm clips such as Silver has been replaced by metals such as Cobalt and Titanium. Innovations in technology and raw material have resulted in the launch of advanced aneurysm clips that are easy and convenient to use and offer enhanced patient comfort.

Increasing cases of brain aneurysm at a global level is another factor boosting the adoption of aneurysm clips across hospitals and healthcare facilities. Aneurysm is common among people in the age bracket 35 to 60 years and a significant increase in the global geriatric population is fueling the demand for neurointerventional devices such as aneurysm clips. Technologically advanced aneurysm clips are used by healthcare practitioners to treat brain aneurysm and this is fueling sales of aneurysm clips across the world.

“The significant contribution of the internet and social media has led to a structured dissemination of information pertaining to aneurysm and effective ways to treat the condition, such as the use of aneurysm clips. Information on clinical management of aneurysm, availability and pricing of aneurysm clips, product feedback from physicians, R&D in product development, and defects in material compatibility is easily available to the general population on open source medical websites as well as on aneurysm clips manufacturer websites. This has created increasing awareness and confidence among patients of aneurysm leading to widespread product and treatment adoption; and is one of the key factors boosting growth in revenue of the global aneurysm clips market.” --- Practice Head – Medical Devices, Persistence Market Research

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25471

Key Insights from PMR’s Report on the Aneurysm Clips Market

The global aneurysm clips market is witnessing an increasing adoption of temporary aneurysm clips over permanent clipping. Temporary clipping helps reduce the risk of blood loss and obscuration of the operative area in the event of a rupture and hence is preferred by physicians in certain cases.
Another trend being witnessed is the growing adoption of titanium aneurysm clips over plastic and cobalt clips, despite the high pricing associated with titanium aneurysm clips.
The global market for aneurysm clips is highly consolidated at the top level with massive fragmentation being observed at the bottom of the pyramid – leading to competitive product pricing. Prices of aneurysm clips in the U.S are relatively high while the pricing structure in emerging markets is fairly low owing to the availability of branded as well as locally manufactured aneurysm clips. A competitive pricing structure is largely defined by the availability of a wide range of aneurysm clips in different sizes and shapes manufactured using different types of raw material and incorporating the latest technological innovations.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Dental Preventive Supplies Market Expected To Account For US$ 1,058.9 Mn By 2026

2020-06-17T10:04:40.818Z

Increase in the number of dental clinics in developed countries plays a significant role in the growth of the dental preventive supplies market. Various activities and programs, which support the dental preventive measures, are also expected to drive the growth of the dental preventive supplies market.

Increased awareness regarding oral diseases and prevalence of dental caries mainly due to unhealthy lifestyle, smoking, and excessive consumption of alcohol among the young population also play a vital role in boosting the growth of the dental preventive supplies market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/24337

Compan Profiles

3M Company
Tepe oral hygiene products Ltd .
Kavo Kerr Corporation
Dentsply Sirona
Ivoclar vivadent AG
Preventive Technologies , Inc .
Dental Technologies , Inc.
Young Innovations , Inc .
GC Corporation
Cantel Medical
Others.

There is an increase in the demand for dental products among graying population, which creates enormous growth opportunities for the manufactures in the dental preventive supplies market. An increase in the demand for dental products among graying population creates enormous opportunities for the manufactures. Improved life expectancies of graying population is also expected to be a driving factor for the growth of the dental preventive supplies market.

Increase in the prevalence of dental decay and usage of preventive care products is expected to boost the growth of the market for dental preventive supplies in future. Frequent use of fluoride gels and sealants increases the demand for preventive dental products such as fluoride gels, antimicrobial varnish, sealants, and mouth gel, among others, which is also expected to drive the growth of the market for dental preventive supplies over the forecast period.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/24337

However, low popularity of dental care in low-income countries is expected to restrain the growth of the dental preventive supplies market. Besides, the access to dental preventive products in low- and middle-income countries is less, which is also expected to limit the growth of the dental preventive supplies market.

The companies operating in the dental preventive supplies market are focusing on unparalleled education courses to enhance current skill sets and expand into new competencies. Many companies are actively involved in collaborations to introduce new dental devices in dental preventive supplies market.

PMR has segmented the Dental Preventive Supplies market on the basis of product type, distribution channels and regions. Based on product type, the dental preventive supplies market has been segmented into dental fluorides, sealants, mouth gel, prophylactic paste & powder, tooth whitening and desensitizers, antimicrobial varnish, dental floss and others. Tooth whitening and desensitizers hold the largest market share in dental preventive supplies market.

Dental fluoride strengthen the tooth enamel and makes it more resistant to tooth decay. Dental sealants are plastic coatings that are usually placed on the chewing surface of the permanent back teeth, which protect them from decaying. Mouth gels provide fast and effective pain relief from common mouth ulcers, sore gums and denture rubbing. Dental floss is a thin, soft thread used to remove food and dental plaque.

Varnishes can be defined as coating materials that are applied to surfaces in a thin layer. The others segment includes other preventive products such as air polishing powder, wipes, and tooth crème, among others. On the basis of distribution channel, the dental preventive supplies market is segmented into drug stores, retail pharmacies and e-commerce.

Geographically, the global dental preventive supplies market has been segmented across regions, namely North America, Latin America, Europe, and Asia Pacific excluding China, China and MEA. North America, followed by Asia Pacific, is expected to hold substantial revenue share in the global dental preventive supplies market.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/24337

North America holds the largest market share in dental preventive supplies market. Companies are focusing on increasing their market share in emerging regions such as CIS & Russia and APEJ, among others.

Based on the end users, the dental preventive supplies market is segmented into drug stores, retail pharmacies and e-commerce. The indirect sales hold large market share in dental preventive supplies market.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Humanized Liver Mice Model Market Accounting For US$ 22.8 Mn By 2026

2020-06-17T10:04:36.828Z

A large number of humanized liver mice models are available, including uPA-SCID mice, FRG KO mice, and TK-NOG mice, among others. Factors such as increasing incidence of liver cirrhosis, technological advancement and development of new humanized liver mice models, increase in number of FDA approvals for liver-based disease treatment dugs have increased the number of research and development activities, which require these models.

However, the high cost of mice models as well as high shipping cost, and availability of alternatives are factors expected to hinder the growth of the humanized liver mice model market during the forecast period. Furthermore, regulatory challenges including patenting of mice and other ethical issues including the use of 3Rs policy are also expected to restrain the growth of the humanized liver mice model market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25417

Company Profiles

Taconic Biosciences, Inc.
Beijing Vitalstar Biotechnology Co., Ltd.
Yecuris Corporation
PhoenixBio Group
In-Vivo Science Inc.
The Jackson Laboratory
University of Massachusetts Medical School(Mueller Lab)
Oncodesign
University of Nebraska Medical Center
Others.

The global humanized liver mice model market is projected to account for over US$ 22.8 Mn in terms of value by 2026 end, according to a latest research by PMR. The report on the global humanized liver mice model market further projects significant growth potential with average year-on-year growth rate of 4.6% through 2026.

Albumin enhancer/promoter-driven urokinase-type plasminogen and activator/severe combined immunedeficient mice are known as the uPA-SCID mice. These mice suffer from a transgene-induced liver disease, and are transplanted with primary human hepatocytes immediately after birth.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25417

These mice were one of the first humanized liver mice model developed with high chimerism and are the most common type of humanized liver mice models available. The TK-NOG mice are designed to express a Herpes Simplex Virus-1 Thymidine Kinase (HSVtk) transgene that is primarily driven by the albumin enhancer/promoter in the liver of the mice. This induces liver-specific injury when treated with gancyclovir.

Human liver cells are then introduced into the liver of the mouse to replace the liver cells that are destroyed. The other type of humanized liver mice model that is gaining popularity is the FRG KO mice. The FRG KO mice are developed by knocking out three genes including Fah-/-; Rag2-/-; and Il2rg-/-.

These mice overcome some of the drawbacks of the uPA-SCID mice such a low breeding capacity and genotype reversion. These mice have a slightly better breeding capacity and cannot undergo genotype reversion allowing the human hepatocytes to be serially transplanted into other mice. These humanized liver mice models also show high chimerism like the uPA-SCID mice.

PMR has segmented the global humanized liver mice model market based on model, application, end user and region. The humanized liver mice model by model is further sub-segmented into uPA-SCID Mice, FRG KO Mice, TK-NOG Mice, and other models. Based on end users, the humanized liver mice model market is segmented into pharmaceutical companies, biotechnology companies, CRO’s and academic & research institutes.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25417

CRO’s segment is expected to hold maximum share in the global humanized liver mice model market followed by academic &research institutes segment. Based on application, the humanized liver mice model market is segmented into pharmacokinetic studies, in-vivo liver toxicity testing, drug metabolism studies, and other applications.

North America is expected to be the dominant regional market for humanized liver mice model. This is due to the support for research activities by the government as well as private sectors.

Government funding and support for patenting genetically modified mice are other factors that support the growth of the humanized liver mice model market in North America. China is also expected to be a lucrative regional market for humanized liver mice model due to the changing regulations of the government to support the pharmaceutical and biopharmaceutical industries in the region.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us:

Sleep Aid Devices Market To Exceed US$ 29,200 Mn By 2026

2020-06-17T10:04:33.332Z

According to the American Sleep Association, around 50-70 million adults in the U.S. are suffering from sleep disorders, 48.0% of the U.S. adults report snoring, and approximately 5.9 million U.S. adults were diagnosed with obstructive sleep apnea (OSA).

In Latin America, the prevalence of OSA was 23.5% in 2013. Sleep aid devices are considered as useful tools for the treatment of sleep disorders. According to the latest research by Persistence Market Research (PMR), the global sleep aid devices market is anticipated to account for over US$ 29,200 Mn, in terms of value, by 2026 end. The report on the sleep aid devices market further projects significant growth potential with CAGR at 4.9% through 2026.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25411

Company Profile

ResMed Inc.
Fisher & Paykel Healthcare Limited
Drive DeVilbiss Healthcare LLC
Koninklijke Philips N.V.
Sleep Number Corporation
Responsive Surface Technology LLC
Eight Sleep Inc.
Simmons Bedding Company LLC
Electromedical Products International, Inc.
Kingsdown, Inc.
Ebb Therapeutics
Sleepace Inc.
Others.

Rising stress levels and the rapid increase in sleep disorders such as, insomnia, sleep apnea, restless legs syndrome, narcolepsy, and sleep deprivation have created a need for more advanced sleep aid devices. Various government and non-government organizations such as Circadian Sleep Disorders Network and American Sleep Apnea Association (ASAA) are conducting various awareness programs to increase awareness regarding the importance of ample sleep and usage of sleep aid devices.

The initiatives taken by sleep associations and government authorities are promoting the demand for sleep disorder treatment. This would result in an increasing wave of demand for sleep aid devices.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25411

The rise in geriatric population is expected to contribute to the growth of sleep aid devices market. As per the NIH-funded Census Bureau report in 2016, around 8.5% of the world population was aged 65 or above and by 2050 this percentage is expected to grow to around 17%.

The prevalence of several lifestyle diseases such as atherosclerosis, heart disease, stroke, obesity, type 2 diabetes, and diseases associated with smoking, alcohol and drug abuse is rising globally. The rise in geriatric population and other lifestyle-related diseases is consequently expected to impact the growth of the sleep aid devices market in a positive way.

Disposable income in developing economies is increasing, as a result, people are opting for safe and advanced sleep aid devices. Moreover, due to the rise in disposable income, people now can afford the high-cost devices. Such favorable conditions have provided an excellent growth opportunity for the manufacturers of sleep aid devices to connect with potential customers.

Persistence Market Research (PMR) has segmented the sleep aid devices market based on product type, indication, end user, and region.

The product type segment of the sleep aid devices market is segmented into Positive Air Pressure Devices, Adaptive Servo-Ventilation (ASV) Devices, Mattresses and Pillows, Smart Sleeping Equipment, and Other Sleep Solutions. Smart sleeping equipment are technologically-advanced sleep aid devices, which track sleep and give information about the quality of sleep a person had with the help of a mobile application.

Along with sleep data, they also have some additional features such as onboard temperature control, smart home integration, and can analyze heart and breathing rate to help a person sleep properly. The smart sleeping equipment segment in the sleep aid devices market is expected to witness noteworthy growth in terms of revenue owing to the rapid increase in demand for safe sleep aid devices.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25411

By indication, sleep aid devices can be segmented as sleep aid devices for insomnia, sleep aid devices for sleep apnea, sleep aid devices for restless leg syndrome, sleep aid devices for narcolepsy, and sleep aid devices for sleep deprivation. Insomnia is the most common sleep disorder among these, with short-term issues reported by about 30% of adults and chronic insomnia by 10% in the U.S.

North America and Europe sleep aid devices markets will continue to dominate owing to favorable reimbursement coverage and increasing per capita healthcare expenditure. The Asia Pacific and Latin America sleep aid devices market is expected to grow at a high growth rate due to active healthcare landscape and favorable government policies for startup companies.

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Feminine Hygiene Product Market – Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash. For More Information

Contact us: